Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer, Chattem Sneeze At NAD Decision On Claritin And Nasacort Comparison

This article was originally published in The Tan Sheet

Executive Summary

NAD’s review of Bayer’s Claritin and Claritin-D ads upsets Bayer and challenger Chattem as both appeal the decision to the National Advertising Review Board. Bayer argues it supports the claim nothing “works faster” than Claritin-D, while Chattem says Bayer does not support claiming Claritin-D “starts to work on allergies in 30 minutes.”

You may also be interested in...



Bayer Supports Claritin-D Indications Claim, Not Superiority Over GSK's Flonase

Bayer supports making an “8 versus 6 FDA-approved indications” comparison with GSK's Flonase ,but it fails when suggesting Flonase doesn't relieve "sinus congestion and pressure” and “itchy throat” based only on GSK's competing product not receiving FDA approval for those indications, says NAD.

Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review

Claims that Sanofi's Xyzal 24 HR OTC product contains the same effectiveness as competitor Zyrtec but with half the medication fail a US

National Advertising Division review. NAD also recommended modifying claims suggesting Xyzal's pharmacological design confers a clinically meaningful benefit over Zyrtec.

Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review

Claims that Sanofi's Xyzal 24 HR OTC product contains the same effectiveness as competitor Zyrtec but with half the medication fail a US

National Advertising Division review. NAD also recommended modifying claims suggesting Xyzal's pharmacological design confers a clinically meaningful benefit over Zyrtec.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107637

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel